Arginine Butyrate(Arginine Butyrate) - 药物靶点：TK_在研适应症：短肠综合征_专利_临床

概要

基本信息

药物类型

小分子化药

别名

靶点

TK

作用方式

刺激剂

作用机制

thymidine kinase刺激剂(胸苷激酶刺激剂)

治疗领域

消化系统疾病内分泌与代谢疾病其他疾病

在研适应症

短肠综合征

非在研适应症

镰状细胞血症β地中海贫血爱泼斯坦-巴尔病毒阳性淋巴瘤+ [2]

原研机构

Boston University

在研机构

Baxter Healthcare Corp.

非在研机构

Boston UniversityHemaQuest Pharmaceuticals, Inc.

权益机构-

最高研发阶段临床前

首次获批日期-

最高研发阶段(中国)-

特殊审评孤儿药 (美国)

登录后查看时间轴

结构/序列

分子式C10H22N4O4

InChIKeyHTWPXGKLFMPZHG-WCCKRBBISA-N

CAS号80407-72-3

关联

5

项与 Arginine Butyrate 相关的临床试验

NCT00992732

/ Terminated临床2期

A Phase 2a Open-Label Multi-Center Study Evaluating HQK-1004 Administered With Valganciclovir in Patients With Relapsed or Refractory Epstein-Barr Virus-Positive Lymphoid Malignancies or Lymphoproliferative Disorders

The purpose of this study is to determine if treatment with HQK-1004 and valganciclovir will result in complete or partial responses in patients with EBV-positive lymphoid malignancies or lymphoproliferative disorders.

开始日期2010-05-01

申办/合作机构

HemaQuest Pharmaceuticals, Inc.

NCT00917826

/ Terminated临床2期

A Phase II Trial of Low-Dose Arginine Butyrate and Ganciclovir/Valganciclovir in EBV(+)Lymphoid Malignancies

The purpose of this study is to assess whether administration of Arginine Butyrate + ganciclovir/valganciclovir for up to three 21-day cycles is tolerable, and results in partial or complete responses in patients with EBV(+) lymphoid malignancies.

开始日期2008-09-01

申办/合作机构

HemaQuest Pharmaceuticals, Inc.

[+1]

NCT00006136

/ Completed临床2期IIT

Phase II Study of Arginine Butyrate With or Without Epoetin Alfa in Patients With Thalassemia Intermedia

OBJECTIVES: I. Determine whether arginine butyrate with or without epoetin alfa can stimulate gamma-globin chain production to a degree that decreases anemia and results in hematologic improvement in patients with thalassemia intermedia.
II. Determine whether a proportional increase in gamma-globin synthesis and mRNA and an improvement in nonalfa and alfaglobin chain imbalance by at least 10% over baseline correlate with improved hematologic response in these patients when treated with this regimen.
III. Determine whether a decrease in hemolysis, as assayed by a decrease in LDH, compared to baseline levels correlates with improved hematologic response in these patients when treated with this regimen.
IV. Determine whether any particular genotypes are more responsive than others to this therapy in these patients.
V. Determine whether baseline epoetin alfa levels, gender, and/or baseline reticulocyte counts (or percent circulating nucleated erythroblasts) correlate with improved hematologic response in these patients when treated with this regimen.

开始日期1999-03-01

申办/合作机构

Boston University

100 项与 Arginine Butyrate 相关的临床结果

登录后查看更多信息

100 项与 Arginine Butyrate 相关的转化医学

登录后查看更多信息

100 项与 Arginine Butyrate 相关的专利（医药）

登录后查看更多信息

112,265

项与 Arginine Butyrate 相关的文献（医药）

2025-12-31·Journal of the International Society of Sports Nutrition

Effects of different dietary supplements on athletic performance in soccer players: a systematic review and network meta-analysis

Review

作者: Luo, Hua ; Xiang, Changqing ; Zhu, Xiaolin ; Nasharuddin, Nurul Amelina ; Tengku Kamalden, Tengku Fadilah

BACKGROUNDAs dietary supplements play a crucial role in meeting the unique nutritional needs of soccer players, a growing body of studies are exploring the effects of dietary supplements on athletic performance in soccer players. The effectiveness of certain supplements, such as caffeine and creatine, remains debated due to inconsistent results across studies. Therefore, this systematic review and Bayesian network meta-analysis was conducted to tentatively identify the most effective dietary supplements for soccer players.METHODSWe searched PubMed, Web of Science, Cochrane, Embase, and SPORTDiscus from database establishment to 5 February 2024 to identify randomized controlled trials (RCTs) evaluating the effects of different dietary supplements on athletic performance in soccer players. The risk of bias was assessed using the revised Cochrane risk-of-bias tool for randomized trials. A Bayesian network meta-analysis was performed using the R software and Stata 18.0. A subgroup analysis was conducted based on the competitive level of the athletes.RESULTSEighty RCTs were included, with 1,425 soccer players randomly receiving 31 different dietary supplements or placebo. The network meta-analysis showed that compared with placebo, carbohydrate + protein (SMD: 2.2, very large), carbohydrate + electrolyte (SMD: 1.3, large), bovine colostrum (SMD: moderate) and caffeine (SMD: 0.29, small) were associated with a significant effect on increasing the distance covered. Kaempferia parviflora (SMD: 0.46, small) was associated with a significant effect on enhancing muscular strength. Beta-alanine (SMD: 0.83, moderate), melatonin (SMD: 0.75, moderate), caffeine (SMD: 0.37, small), and creatine (SMD: 0.33, small) were associated with a significant effect on enhancing jump height. Magnesium creatine chelate (SMD: -3.0, very large), melatonin (SMD: -1.9, large), creatine + sodium bicarbonate (SMD: -1.4, large), and arginine (SMD: -1.2, moderate) were associated with a significant effect on decreasing sprint time. Creatine + sodium bicarbonate (SMD: -2.3, very large) and caffeine (SMD: -0.38, small) were associated with a significant effect on improving agility. Sodium pyruvate (SMD: 0.50, small) was associated with a significant effect on increasing peak power. Magnesium creatine chelate (SMD: 1.3, large) and sodium pyruvate (SMD: 0.56, small) were associated with a significant effect on increasing mean power. Carbohydrate + electrolyte (SMD: -0.56, small) was associated with a significant effect on improving the rating of perceived exertion.CONCLUSIONSThis study suggests that a range of dietary supplements, including caffeine, creatine, creatine + sodium bicarbonate, magnesium creatine chelate, carbohydrate + electrolyte, carbohydrate + protein, arginine, beta-alanine, bovine colostrum, Kaempferia parviflora, melatonin, and sodium pyruvate, can improve athletic performance in soccer players. This review provides evidence-based guidance for soccer coaches and nutritionists on using dietary supplements to enhance specific performance measures.

2025-12-31·mAbs

Analysis of how antigen mutations disrupt antibody binding interactions toward enabling rapid and reliable antibody repurposing

Article

作者: Pantazes, Robert J. ; Islam, Sumaiya ; Chauhan, Varun M.

Antibody repurposing is the process of changing a known antibody so that it binds to a mutated antigen. One of the findings to emerge from the Coronavirus Disease 2019 (COVID-19) pandemic was that it was possible to repurpose neutralizing antibodies for Severe Acute Respiratory Syndrome, a related disease, to work for COVID-19. Thus, antibody repurposing is a possible pathway to prepare for and respond to future pandemics, as well as personalizing cancer therapies. For antibodies to be successfully repurposed, it is necessary to know both how antigen mutations disrupt their binding and how they should be mutated to recover binding, with this work describing an analysis to address the first of these topics. Every possible antigen point mutation in the interface of 246 antibody-protein complexes were analyzed using the Rosetta molecular mechanics force field. The results highlight a number of features of how antigen mutations affect antibody binding, including the effects of mutating critical hotspot residues versus other positions, how many mutations are necessary to be likely to disrupt binding, the prevalence of indirect effects of mutations on binding, and the relative importance of changing attractive versus repulsive energies. These data are expected to be useful in guiding future antibody repurposing experiments.

2025-12-31·Journal of the International Society of Sports Nutrition

Investigation of the effect of nitrate and L-arginine intake on aerobic, anaerobic performance, balance, agility, and recovery in elite taekwondo athletes

Article

作者: Buzdağlı, Yusuf ; Savaş, Adem ; Ozan, Murat ; Uçar, Halil ; Kavcı, Zafer

BACKGROUNDTaekwondo is a complex martial art that requires speed, balance, agility, and endurance. This study aims to examine the effects of nitrate and L-arginine supplementation on acute aerobic and anaerobic performance, balance, agility, and recovery in elite taekwondo athletes.METHODThis study was conducted as a double-blind, randomized, crossover study with the participation of 15 experienced taekwondo athletes aged 19.06 ± 0.96 years and 8.93 ± 1.27 years of training experience. Participants visited the laboratory a total of nine times, including a practice session and anthropometric measurements. These visits consisted of eight experimental sessions conducted at 72-hour intervals. The experimental sessions were conducted with nitrate, L-arginine, and a combination of both supplements (NIT*L-ARG) and placebo. Nitrate supplementation was provided by homogenizing fresh spinach (837.40 mg/kg), while L-ARG was given as a single dose of 6 g in powder form three hours before exercise.RESULTSNIT*L-ARG supplementation significantly improved the anaerobic performance of athletes in Wingate peak power and peak power (w/kg) compared to placebo and in mean power compared to NIT, L-ARG, and PLA. In addition, NIT*L-ARG supplementation significantly improved blood lactate levels and agility performance immediately after Wingate and Shuttle run tests.CONCLUSIONThe combined intake of NIT*L-ARG was found to be effective in improving aerobic, anaerobic, and agility performances as well as fatigue levels of athletes. It was determined that taking NIT and L-ARG supplements alone contributed to the improvement of improving athletes' performance in Wingate mean power values and subsequent fatigue level compared to PLA.

100 项与 Arginine Butyrate 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
爱泼斯坦-巴尔病毒阳性淋巴瘤	申请上市	美国	HemaQuest Pharmaceuticals, Inc.	2010-05-01
EBV相关淋巴瘤	申请上市	美国	HemaQuest Pharmaceuticals, Inc.	2008-09-01
短肠综合征	临床前	美国	Baxter Healthcare Corp.	2023-03-09
镰状细胞血症	临床前	美国	Boston University	1997-09-01
β地中海贫血	临床前	美国	Boston University	1997-09-01
下肢溃疡	临床前	美国	Boston University	1997-09-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00004412 (CTgov)	临床2期	β地中海贫血 \| 下肢溃疡 \| 镰状细胞血症	23	Standard local care dressing (Standard Local Care Dressing)	衊範壓築衊鹽餘繭鹹憲(鏇積艱顧膚艱選衊鑰築) = 願襯願糧觸範積齋餘夢襯遞簾製選築築選憲鏇 (糧壓醖餘顧遞餘鏇鏇艱, 衊糧蓋網網範製積醖艱 ~ 鏇淵範醖鹽憲鹹範製鏇) 更多	-	2015-03-31
NCT00004412 (CTgov)	临床2期	β地中海贫血 \| 下肢溃疡 \| 镰状细胞血症	23	Standard local care dressing+Arginine Butyrate (Arginine Butyrate)	衊範壓築衊鹽餘繭鹹憲(鏇積艱顧膚艱選衊鑰築) = 鬱構觸範廠淵廠繭膚鏇襯遞簾製選築築選憲鏇 (糧壓醖餘顧遞餘鏇鏇艱, 顧餘廠選衊壓襯遞醖簾 ~ 憲齋膚襯糧鏇鏇繭願餘) 更多	-	2015-03-31
Pubmed \| Br J Haematol	临床2期	下肢溃疡	-	Arginine Butyrate (Standard local care)	夢糧淵膚艱襯淵願鑰餘(遞鏇遞構醖夢襯築齋網) = 構鬱蓋遞鹽構遞醖夢衊構鹽廠膚製襯夢憲願獵 (糧製蓋夢鹽齋獵艱顧壓 )	-	2010-12-01
Pubmed \| Br J Haematol	临床2期	下肢溃疡	-	Standard care with Arginine Butyrate	夢糧淵膚艱襯淵願鑰餘(遞鏇遞構醖夢襯築齋網) = 築構獵壓範夢鹽遞廠選構鹽廠膚製襯夢憲願獵 (糧製蓋夢鹽齋獵艱顧壓 )	-	2010-12-01
Pubmed \| Blood	临床1/2期	爱泼斯坦-巴尔病毒相关肿瘤	15	Arginine butyrate	(艱憲築鹹簾廠艱選積淵) = 餘廠繭範蓋簾夢夢觸壓簾鏇構廠積願蓋鹽鏇醖 (網願鑰鹽觸壓膚範餘鹹 )	-	2007-03-15
ASCO2006	临床1/2期	爱泼斯坦-巴尔病毒相关肿瘤	-	Arginine Butyrate	(獵壓蓋窪襯餘構膚製壓) = 淵齋襯觸築艱簾獵糧夢憲觸夢衊餘願窪繭鹹憲 (製遞鑰遞築選壓鹹範廠 )	-	2006-06-20